Shefali Agarwal M.D., MPH
Net Worth

Last updated:

What is Shefali Agarwal M.D., MPH net worth?

The estimated net worth of Dr. Shefali Agarwal M.D., MPH is at least $4,548,788 as of 9 Aug 2022. He owns shares worth $228,322 as insider, has earned $210,706 from insider trading and has received compensation worth at least $4,109,760 in Epizyme, Inc..

What is the salary of Shefali Agarwal M.D., MPH?

Dr. Shefali Agarwal M.D., MPH salary is $684,960 per year as Executive Vice President and Chief Medical & Devel. Officer in Epizyme, Inc..

How old is Shefali Agarwal M.D., MPH?

Dr. Shefali Agarwal M.D., MPH is 51 years old, born in 1974.

What stocks does Shefali Agarwal M.D., MPH currently own?

As insider, Dr. Shefali Agarwal M.D., MPH owns shares in one company:

Company Title Shares Price per share Total value
Epizyme, Inc. (EPZM) Executive Vice President and Chief Medical & Devel. Officer 156,385 $1.46 $228,322

What does Epizyme, Inc. do?

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

EPZM logo
EPZM
Epizyme, Inc.
$1.46

Shefali Agarwal M.D., MPH insider trading

Epizyme, Inc.

Dr. Shefali Agarwal M.D., MPH has made 12 insider trades between 2019-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 400,000 units of EPZM stock on 9 Aug 2022. As of 9 Aug 2022 he still owns at least 156,385 units of EPZM stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 400,000 $1.39 $556,000
Option
Common Stock, par value $0.0001 56,527 $1.39 $78,573
Option
Common Stock, par value $0.0001 43,473 $1.39 $60,427
Option
Stock Option (Right to Buy) 43,473 $1.39 $60,427
Option
Stock Option (Right to Buy) 56,527 $1.39 $78,573
Option
Common Stock, par value $0.0001 400,000 $1.39 $556,000
Sale
Common Stock, par value $0.0001 1,058 $1.5 $1,587
Sale
Common Stock, par value $0.0001 2,639 $1.37 $3,615
Sale
Common Stock, par value $0.0001 2,922 $2.02 $5,902
Sale
Common Stock, par value $0.0001 1,780 $2.93 $5,215
Sale
Common Stock, par value $0.0001 969 N/A N/A
Sale
Common Stock, par value $0.0001 2,872 $11.41 $32,770
Sale
Common Stock, par value $0.0001 2,522 N/A N/A
Sale
Common Stock, par value $0.0001 1,805 $16.15 $29,151
Sale
Common Stock, par value $0.0001 1,243 $15.28 $18,993
Sale
Common Stock, par value $0.0001 2,630 $20.44 $53,757
Sale
Common Stock, par value $0.0001 1,843 $24.64 $45,412
Sale
Common Stock, par value $0.0001 1,195 $11.97 $14,304

Epizyme key executives

Epizyme, Inc. executives and other stock owners filed with the SEC: